IBDEI14D ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19752,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,19753,0)
 ;;=V12.59^^105^1235^30
 ;;^UTILITY(U,$J,358.3,19753,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19753,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,19753,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,19753,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,19754,0)
 ;;=V45.81^^105^1235^29
 ;;^UTILITY(U,$J,358.3,19754,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19754,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,19754,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,19754,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,19755,0)
 ;;=V15.84^^105^1235^28
 ;;^UTILITY(U,$J,358.3,19755,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19755,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,19755,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,19755,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,19756,0)
 ;;=V15.85^^105^1235^47
 ;;^UTILITY(U,$J,358.3,19756,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19756,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,19756,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,19756,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,19757,0)
 ;;=V10.72^^105^1235^34
 ;;^UTILITY(U,$J,358.3,19757,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19757,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,19757,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,19757,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,19758,0)
 ;;=V15.3^^105^1235^35
 ;;^UTILITY(U,$J,358.3,19758,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19758,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,19758,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,19758,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,19759,0)
 ;;=V10.61^^105^1235^37
 ;;^UTILITY(U,$J,358.3,19759,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19759,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,19759,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,19759,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,19760,0)
 ;;=V12.03^^105^1235^39
 ;;^UTILITY(U,$J,358.3,19760,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19760,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,19760,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,19760,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,19761,0)
 ;;=V10.82^^105^1235^40
 ;;^UTILITY(U,$J,358.3,19761,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19761,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,19761,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,19761,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,19762,0)
 ;;=V10.62^^105^1235^43
 ;;^UTILITY(U,$J,358.3,19762,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19762,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,19762,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,19762,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,19763,0)
 ;;=V10.63^^105^1235^41
 ;;^UTILITY(U,$J,358.3,19763,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19763,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,19763,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,19763,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,19764,0)
 ;;=V11.2^^105^1235^32
 ;;^UTILITY(U,$J,358.3,19764,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19764,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,19764,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,19764,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,19765,0)
 ;;=V15.81^^105^1235^60
 ;;^UTILITY(U,$J,358.3,19765,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19765,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,19765,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,19765,2)
 ;;=^295290
 ;;
 ;;$END ROU IBDEI14D
